Sanofi Share Price & Technical Analysis
SNY · $44.29 (-1.40%)
Healthcare / Drug Manufacturers - General
$44.29
-1.40%
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typ…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-5% return in May, -5% avg return in past 3 year May month.
-8% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | 2% | 0% | -3% | -5% | – | – | – | – | – | – | – | -8% |
| 25 | 12% | 2% | -1% | -1% | -10% | -1% | -5% | 8% | -5% | 4% | -1% | -4% | -3% |
| 24 | 1% | -1% | 3% | 0% | 0% | 0% | 5% | 10% | 0% | -8% | -10% | 0% | -1% |
| 23 | 1% | -4% | 15% | -1% | -5% | 7% | -1% | -1% | -1% | -16% | 3% | 7% | 4% |
| 22 | 3% | 2% | 0% | 1% | 1% | -7% | -1% | -16% | -6% | 12% | 5% | 5% | -2% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Neutral
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$102.85B
P/E ratio
18.42
52W high
$53.03
52W low
$42.33
Volume
27,63,267
Beta
0.28
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Sanofi share price today?
- Sanofi (SNY) last traded around $44.29 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SNY have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SNY. Download the app for real-time alerts.
- How can I analyze Sanofi stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.